Bristol-Myers Squibb News

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Orderbuch			Analysen
Historisch

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Strukturierte Produkte

Aktion

Portfolio

Watchlist

20.10.09	New Data Describe Safety of Subcutaneous Administration of ORENCIA® (abatacept) For Patients with Moderate to Severe Rheumatoid Arthritis (Businesswire)
19.10.09	ORENCIA® (abatacept) Demonstrated Sustained Clinical Response in a Study of Adult Patients with Moderate to Severe Early Rheumatoid Arthritis (Less Than Two Years Duration) (Businesswire)
21.08.09	Bristol-Myers Squibb verlängert Annahmefrist für Medarax-Übernahme (dpa-afx)
23.07.09	Excellent Performance Highlights Second Quarter for Bristol-Myers Squibb (Businesswire)
23.07.09	Bristol-Myers kündigt Übernahme von Medarex an (Aktiencheck)
12.06.09	ORENCIA® (abatacept) DEMONSTRIERT KONSISTENTE SICHERHEIT UND WIRKSAMKEIT ÜBER 7 JAHRE HINWEG (Businesswire)
12.06.09	ORENCIA® (abatacept) DEMONSTRATES CONSISTENT SAFETY AND EFFECTIVENESS OVER 7 YEARS (Businesswire)
14.05.09	SPRYCEL® (Dasatinib) Shows Potential as Treatment for Prostate Cancer (Businesswire)
27.01.09	Bristol-Myers meldet drastischen Ergebnisanstieg (Aktiencheck)
27.01.09	Strong Fourth Quarter Supports Excellent 2008 for Bristol-Myers Squibb (Businesswire)
06.11.08	Rationale and Design of CURRENT-OASIS 7 Study Published in American Heart Journal (Businesswire)
02.11.08	New Data Suggest Long-Term Treatment with BARACLUDE(R) (entecavir) May Reduce Liver Damage Caused by Chronic Hepatitis B (Businesswire)
28.10.08	Data Demonstrate ORENCIA(R) (abatacept) Improves Health-Related Quality of Life, Pain and Sleep Quality in Children With Juvenile Idiopathic Arthritis (Businesswire)
23.10.08	Bristol-Myers Squibb Continues Excellent Financial Performance Led By Double-Digit Global Net Sales Growth and Strong Earnings Results (Businesswire)
06.10.08	Bristol-Myers Squibb Comments on Eli Lilly as New Erbitux Marketing Partner (Businesswire)
01.10.08	U.S. Food & Drug Administration Approved the use of REYATAZ(R) (atazanavir sulfate) Boosted with Ritonavir, in Combination Therapy, for Previously Untreated HIV-1 Infected Adult Patients (Businesswire)
01.10.08	Thirteen Advocacy Groups Collaborate on New Online Resource Dedicated to Patients with Advanced Breast Cancer (Businesswire)
13.08.08	ADDING MULTIMEDIA NJ, CT, NY & MD School Districts Join Program That Teaches High School Students How Medicines Are Made (Businesswire)
12.06.08	ORENCIA(R) (abatacept) Provided an Increasing Degree of Inhibition of Structural Damage Through Three Years in Adults with Moderate to Severe Rheumatoid Arthritis (Businesswire)
13.05.08	Bristol-Myers Squibb and KAI Pharmaceuticals Enter Global Alliance to Develop and Commercialize KAI-9803 for Cardiovascular Disease (Businesswire)
24.04.08	Strong Double-Digit Net Sales Growth and Solid Earnings Growth Highlight First Quarter for Bristol-Myers Squibb Company (PR Newswire)
31.01.08	Wall Street-Schluss: Kräftige Zugewinne, Quartalszahlen im Fokus (Aktiencheck)
17.12.07	Avista kauft Bristol-Myers Squibb Medical Imaging für 525 Millionen Dollar (dpa-afx)
17.12.07	Avista Capital Partners Agrees to Acquire Bristol-Myers Squibb Medical Imaging for Approximately $525 Million (PR Newswire)
11.12.07	Bristol-Myers Squibb and Gilead Sciences Expand Their Alliance to Include Commercialization of ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) in Europe (Businesswire)
06.12.07	Ausblick: Die Märkte am Donnerstag (Aktiencheck)
05.12.07	Bristol-Myers Squibb Company Outlines Strategy and Productivity Transformation Initiative During Update to Investment Community (PR Newswire)
30.11.07	Bristol-Myers Squibb, New Jersey Children's Hospital Launch Center for Immune System Disorders & Infectious Diseases Including HIV/AIDS (PR Newswire)
14.11.07	New England Journal of Medicine Study Shows ERBITUX(R) Improves Survival in Advanced Colorectal Cancer (PR Newswire)
12.11.07	Post-Hoc Data Show Daily Activity Participation, Independence and Sleep Quality Improved in Adults with Moderate to Severe Rheumatoid Arthritis After Treatment with ORENCIA(R) (Abatacept) (PR Newswire)
09.11.07	FDA Approves New SPRYCEL(R) (Dasatinib) Product Labeling for Patients with Chronic-Phase CML (PR Newswire)
25.10.07	Bristol-Myers Squibb Company Reports Financial Results for the Third Quarter and First Nine Months of 2007 (PR Newswire)
18.10.07	European CHMP Issues Positive Opinion for ATRIPLA(R) (efavirenz 600 mg/ emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) (PR Newswire)
17.10.07	Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV (Businesswire)
17.10.07	Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV (PR Newswire)
03.10.07	Survival Data in FDA Approval for ERBITUX(R) (Cetuximab) Supports Use as a Single Agent in Patients with Advanced Colorectal Cancer (Businesswire)
11.09.07	ERBITUX(R) Meets Primary Endpoint of Increasing Survival in Phase III Lung Cancer Study (PR Newswire)
27.08.07	Pfizer and Bristol-Myers Squibb Finalize Agreement for Worldwide Collaboration on Metabolic Disorders Program (PR Newswire)
26.07.07	Bristol-Myers Squibb Company Reports Financial Results for the Second Quarter and First Half of 2007 (PR Newswire)
17.07.07	ABILIFY(R) (aripiprazole) Supplemental New Drug Application Receives Priority Review by U.S. Food And Drug Administration for Adjunctive Treatment in Adults With Major Depressive Disorder (PR Newswire)
12.07.07	ROUNDUP:Erbitux von Merck-Partner ImClone verfehlt Studienziel bei Lungenkrebs (dpa-afx)
21.05.07	Six-Week Investigational Study In Adults With Major Depressive Disorder Evaluates The Effectiveness of Adjunctive Aripiprazole Therapy With Antidepressants (PR Newswire)
21.05.07	BARACLUDE(R) (Entecavir) Treatment Demonstrated Greater Viral Load Reduction Compared to Adefovir at 48 Weeks in Study of Antiviral-Naive Chronic Hepatitis B E-Antigen Positive Patients (PR Newswire)
26.04.07	Wall Street: Leichte Gewinnmitnahmen, Ford und Apple nach Zahlen deutlich im Plus (Aktiencheck)
26.04.07	Bristol-Myers Squibb and Pfizer Announce Worldwide Collaboration to Develop and Commercialize Anticoagulant and Metabolic Compounds (PR Newswire)
23.04.07	Crohn's Patient Robert Hill Summits Carstensz Pyramid, Sixth in Seven Summits Campaign (PR Newswire)
13.04.07	BARACLUDE(R) (entecavir) Therapy Resulted in Undetectable Levels of Hepatitis B Virus in Cohort of Patients Who Re-Started Treatment (PR Newswire)
30.01.07	Ausblick: Die Märkte am Dienstag (Aktiencheck)
25.01.07	Bristol-Myers Squibb Company Reports Financial Results for the Fourth Quarter and Twelve Months of 2006 and Announces EPS Guidance for 2007 (PR Newswire)
11.01.07	Bristol-Myers Squibb and AstraZeneca Announce Worldwide Collaboration to Develop and Commercialize Diabetes Compounds (PR Newswire)

Newssuche

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Part Grp Hldg	1’263.50	2.89 %	K V
Sonova Hldg	312.10	2.66 %	K V
Novartis	93.68	2.32 %	K V
Geberit	526.80	1.97 %	K V
Roche Hldg G	254.30	1.27 %	K V
Kuehne+Nagel Int	209.50	0.72 %	K V
UBS Group	28.30	0.57 %	K V
Givaudan	3’933.00	0.36 %	K V
Nestle	76.00	0.05 %	K V
Lonza Grp	521.40	-0.04 %	K V

mehr

22.11.24		Dow Jones aktuell: Dow Jones zum Ende des Freitagshandels in der Gewinnzone
22.11.24		SIX-Handel: SLI zeigt sich zum Ende des Freitagshandels fester
22.11.24		Pluszeichen in Zürich: SMI zum Ende des Freitagshandels mit grünem Vorzeichen
22.11.24		Gute Stimmung in Europa: Anleger lassen STOXX 50 letztendlich steigen
22.11.24		Deutsche Bank AG: Novartis-Aktie erhält Hold
22.11.24		Freitagshandel in New York: Dow Jones zum Start des Freitagshandels fester
22.11.24		Optimismus in Europa: So entwickelt sich der Euro STOXX 50 am Freitagnachmittag
22.11.24		Pluszeichen in Europa: STOXX 50 notiert im Plus